ACA
REGN icon

Aptus Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Aptus Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Sell
1,180
-84
-7% -$57.2K 0.01% 686
2026
Q1 		$977K Sell
1,264
-399
-24% -$305K 0.01% 590
2025
Q4 		$1.28M Buy
1,663
+161
+11% +$109K 0.01% 529
2025
Q3 		$845K Sell
1,502
-11
-0.7% -$6.22K 0.01% 581
2025
Q2 		$794K Sell
1,513
-73
-5% -$40.7K 0.01% 573
2025
Q1 		$1.01M Sell
1,586
-13
-0.8% -$8.94K 0.01% 509
2024
Q4 		$1.14M Buy
1,599
+625
+64% +$525K 0.01% 478
2024
Q3 		$1.02M Buy
974
+32
+3% +$35.6K 0.02% 405
2024
Q2 		$990K Buy
942
+39
+4% +$37.8K 0.02% 394
2024
Q1 		$869K Buy
903
+124
+16% +$118K 0.02% 415
2023
Q4 		$684K Sell
779
-25
-3% -$20.6K 0.02% 332
2023
Q3 		$662K Buy
804
+310
+63% +$244K 0.02% 339
2023
Q2 		$355K Buy
494
+40
+9% +$30.8K 0.01% 371
2023
Q1 		$373K Buy
454
+91
+25% +$68.6K 0.01% 353
2022
Q4 		$262K Sell
363
-140
-28% -$103K 0.01% 427
2022
Q3 		$347K Sell
503
-4
-0.8% -$2.52K 0.01% 369
2022
Q2 		$300K Sell
507
-72
-12% -$46.8K 0.01% 326
2022
Q1 		$404K Buy
+579
New +$366K 0.01% 323

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aptus Capital Advisors's REGN Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 6.6% in Q2 2026, selling an estimated $57.2K and leaving 1,180 shares worth $736K. The position accounts for 0.01% of the portfolio, ranked #686.

Aptus Capital Advisors first reported a position in REGN in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.28M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aptus Capital Advisors held 1,180 shares of Regeneron Pharmaceuticals worth $736K as of Q2 2026.
  • Aptus Capital Advisors sold 84 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $57.2K.
  • Regeneron Pharmaceuticals made up 0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #686 holding.
  • Aptus Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Aptus Capital Advisors's Regeneron Pharmaceuticals position peaked at $1.28M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.